证券代码：300261 证券简称：雅本化学 公告编号：2025-034 雅本化学股份有限公司 关于 2023 年员工持股计划首次受让部分及预留受让部分 第一个锁定期解锁条件未成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司")于 2025 年 4 月 21 日召开了第六届 董事会第二次会议和第六届监事会第二次会议，审议通过了《关于 2023 年员工持股 计划首次受让部分及预留受让部分第一个锁定期解锁条件未成就的议案》。根据《雅 本化学股份有限公司 2023 年员工持股计划（草案修订稿）》（以下简称"《2023 年员工持股计划》"或"本员工持股计划"）《雅本化学股份有限公司关于 2023 年员工持股计划预留份额分配的公告》（以下简称"《预留份额分配公告》"）的 相关规定，本员工持股计划首次受让部分及预留受让部分第一个锁定期解锁条件未 成就，对应未解锁的权益份额不得解锁。现将相关事项公告如下： 一、本员工持股计划批准及实施情况 （一）2023年8月24日，公司召开了第五届董事会第十一次会议和第五届监事会 第十次会议 ...

Financial Performance - The company reported a net profit attributable to shareholders of -257.70 million RMB for the year 2024, indicating a significant decline compared to the previous year due to product price fluctuations and intensified market competition [4]. - The company's operating revenue for 2024 was ¥1,202,178,750.59, a decrease of 6.00% compared to ¥1,278,848,252.00 in 2023 [19]. - The net profit attributable to shareholders for 2024 was -¥257,702,742.43, representing a decline of 213.15% from -¥82,293,808.08 in 2023 [19]. - The company's operating profit was CNY -30,815.19 million, down 292.50% year-on-year, and the total profit was CNY -30,890.67 million, a decline of 247.79% [52]. - The net profit attributable to the parent company was CNY -25,770.27 million, representing a decrease of 213.15% compared to the previous year [52]. - The company reported a significant increase in the sales of chemical products, with operating revenue after deductions amounting to ¥1,168,285,996.89 in 2024 [20]. - The company faced challenges in the pesticide industry, with global market growth from $35.575 billion in 2006 to $87.7 billion in 2022, reflecting a compound annual growth rate of approximately 5.80% [29]. - The company reported a total revenue of 2.55 billion in the latest financial period, reflecting a growth of 10.5% compared to the previous year [146]. Dividend and Capital Management - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves for the year [7]. - The company plans to distribute cash dividends of RMB 0.5 per 10 shares, totaling a cash dividend of RMB 481,654.74, which is 0.00% of the total profit distribution [168]. - The company has no plans for cash dividends, stock bonuses, or capital reserve transfers for the 2024 profit distribution [170]. - The company raised a total of RMB 867,109,999.04 through a non-public offering of 105,231,796 shares, with a net amount of RMB 847,613,986.89 after deducting issuance fees [92]. Research and Development - The company has invested significantly in R&D, leading to strong technical advantages and cost efficiencies in the production of its pesticide intermediates [40]. - R&D expenses increased by 2.71% to CNY 12,327.90 million, reflecting the company's commitment to innovation [52]. - The company is focusing on technological innovations in continuous manufacturing and AI-assisted drug design to enhance global competitiveness [32]. - The company is committed to continuous innovation in R&D, focusing on green chemistry processes and continuous flow technology to improve production efficiency and reduce environmental impact [118]. Market and Competitive Landscape - The company's operational performance is under pressure from multiple factors, including market competition and product pricing [4]. - The company noted that despite a competitive market, domestic pesticide production is expected to gain strength with increasing approvals for new pesticide formulations [30]. - The company is actively pursuing certifications such as GMP compliance and Halal certifications to enhance its marketability and compliance [39]. - The company is targeting significant market demand for its new pesticide products, indicating a strong growth potential in the agricultural sector [40]. Environmental and Sustainability Efforts - The company is committed to environmental management and has obtained various environmental certifications, including ISO 14001 [39]. - The company has established comprehensive waste treatment facilities to minimize environmental impact during production activities [179]. - The company has implemented a sustainable procurement system and conducting annual assessments of suppliers to ensure alignment with business needs [120]. - The company is focused on ESG governance, aiming to improve management efficiency and reduce carbon emissions in line with SBTi commitments [121]. Governance and Compliance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements [133]. - The company maintains an independent financial department with a complete accounting system, allowing for independent financial decision-making and tax compliance [139]. - The company has established a governance structure that complies with relevant laws and regulations, with no unresolved governance issues [130]. - The company has implemented an employee stock ownership plan, with 53 employees holding a total of 6,400,000 shares, representing 0.90% of the company's total equity [170]. Operational Efficiency and Capacity - The designed capacity for pesticide intermediates and raw materials is 7,400 tons, with a utilization rate of 27.58% [36]. - The company is currently constructing additional capacity of 700 tons for pesticide intermediates and raw materials [36]. - The company has established six core production bases and two cooperative production bases, optimizing its supply chain and ensuring stable operations [45]. - The company has completed upgrades on certain production lines at the Taicang base, with a total investment of 37,032,000 RMB, achieving a 100% completion rate [100]. Risk Management - The company has detailed potential risks and countermeasures in the management discussion and analysis section of the report [6]. - The company is managing goodwill impairment risks from acquisitions by strengthening governance of subsidiaries and supporting their business development [124]. - The company is addressing potential risks from new project investments by conducting thorough market research and establishing a dedicated project management team [123]. - The company is monitoring exchange rate fluctuations and utilizing financial tools to mitigate risks associated with currency volatility [125].

证券代码：300261 证券简称：雅本化学 公告编号：2025-029 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"） 第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》，为满足子公 司的经营发展需要，公司同意为兰州雅本精细化工有限公司（以下简称"兰雅 精化"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相担保的公 告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股 东大会审议通过了上述议案。 二、担保的进展情况 为满足日常经营发展需要，兰雅精化向交通银行股份有限公司甘肃省分行 （以下简称"交通银行甘肃省分行"）申请不超过人民币 1,000 万元的授信额 度。公司近日与交通银行甘肃省分行续签了《保证合同 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

雅本化学股份有限公司 简式权益变动报告书（马立凡） 上市公司名称：雅本化学股份有限公司 信息披露义务人：马立凡 通讯地址：上海市普陀区中江路 118 弄 22 号海亮大厦 A 座 15 层 股份变动性质：一致行动关系解除 签署日期：2025 年 4 月 2 日 1 上市地点：深圳证券交易所 股票简称：雅本化学 股票代码：300261 目录 | 第一节信息披露义务人声明………………………………………………………3 | | --- | | 第二节释义…………………………………………………………………………4 | | 第三节信息披露义务人介绍………………………………………………………5 | | 第四节权益变动目的及持股计划…………………………………………………7 | | 第五节权益变动方式………………………………………………………………8 | | 第六节前六个月内买卖上市交易股份的情况……………………………………9 | | 第七节其他重大事项………………………………………………………………10 | | 第八节备查文件……………………………………………………………………11 | | 第九节信息披露义务人声明…………… ...

简式权益变动报告书（王卓颖） 上市公司名称：雅本化学股份有限公司 信息披露义务人：王卓颖 雅本化学股份有限公司 上市地点：深圳证券交易所 股票简称：雅本化学 股票代码：300261 目录 | 第一节信息披露义务人声明………………………………………………………3 | | --- | | 第二节释义…………………………………………………………………………4 | | 第三节信息披露义务人介绍………………………………………………………5 | | 第四节权益变动目的及持股计划…………………………………………………7 | | 第五节权益变动方式………………………………………………………………8 | | 第六节前六个月内买卖上市交易股份的情况……………………………………9 | | 第七节其他重大事项………………………………………………………………10 | | 第八节备查文件……………………………………………………………………11 | | 第九节信息披露义务人声明…………………………………………………12 | | 附表一雅本化学股份有限公司简式权益变动报告书附表………………………..13 | 2 第一节信息披露义务人声明 通 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-028 雅本化学股份有限公司 关于股东解除一致行动关系暨公司实际控制人变更 的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次权益变动系王卓颖、马立凡因个人原因，与蔡彤、汪新芽解除一致 行动关系导致其所持有雅本化学股份有限公司（以下简称"公司"或"雅本化学"） 的股份不再与蔡彤、汪新芽合并计算所致。蔡彤、汪新芽、王卓颖、马立凡各自 的持股数量和持股比例不变。 2、本次权益变动不会导致公司控股股东发生变化。本次权益变动不会对公 司日常经营活动产生不利影响；不会对公司主营业务和财务状况产生重大影响； 不会影响公司的人员独立、财务独立和资产完整；公司仍具有规范的法人治理结 构。 一、一致行动关系解除情况 1、一致行动关系的情况说明 2014 年 8 月 13 日，蔡彤、王卓颖、毛海峰、马立凡、汪新芽签署了《一致 行动人协议》，一致同意在持有雅本化学股份期间，对雅本化学的相关事项做出 完全一致的决策。其中蔡彤、王卓颖、毛海峰、马立凡等 4 人共同通过宁波雅本 控股有限公司（以下 ...

雅本化学股份有限公司 简式权益变动报告书（蔡彤、汪新芽） 上市公司名称：雅本化学股份有限公司 信息披露义务人之一：蔡彤 通讯地址：上海市普陀区中江路 118 弄 22 号海亮大厦 A 座 15 层 信息披露义务人之二：汪新芽 通讯地址：上海市浦东新区芳甸路 1155 号浦东嘉里城办公楼 2102 室 股份变动性质：一致行动关系解除 签署日期：2025 年 4 月 2 日 1 上市地点：深圳证券交易所 股票简称：雅本化学 股票代码：300261 目 录 第一节 信息披露义务人声明 一、本报告书系依据《中华人民共和国证券法》、《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》及 相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在雅本化学股份有限公司（以下简称"雅本 化学"）中拥有权益的股份变动情况；截至本报告书签署之日，除本报告书披露 的信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在雅本化学 中拥有权益的股份。 ...

雅本化学（300261）3月24日主力资金净流入 1989.02万元 金融界消息 截至2025年3月24日收盘，雅本化学（300261）报收于7.33元，上涨5.77%，换手率7.7%， 成交量72.06万手，成交金额5.18亿元。 通过天眼查大数据分析，雅本化学股份有限公司共对外投资了9家企业，参与招投标项目18次，知识产 权方面有商标信息35条，专利信息66条，此外企业还拥有行政许可16个。 来源：金融界 资金流向方面，今日主力资金净流入1989.02万元，占比成交额3.84%。其中，超大单净流入406.30万 元、占成交额0.78%，大单净流入1582.72万元、占成交额3.05%，中单净流出流入1414.76万元、占成交 额2.73%，小单净流出3403.77万元、占成交额6.57%。 雅本化学最新一期业绩显示，截至2024三季报，公司营业总收入9.40亿元、同比减少14.59%，归属净利 润5671.97万元，同比减少173.99%，扣非净利润6555.80万元，同比减少208.45%，流动比率1.135、速动 比率0.762、资产负债率41.77%。 天眼查商业履历信息显示，雅本化学股份有限公司， ...